Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference The new mini-textbook by Kamps & Hoffmann PDF, 110 pages

Breast Cancer

Free Subscription Articles published in Cancer Res Retrieve available abstracts of 143 articles: HTML format Text format

Single Articles

March 2020
1. MITOBE Y, Iino K, Takayama KI, Ikeda K, et al
   PSF promotes ER-positive breast cancer progression via posttranscriptional regulation of ESR1 and SCFD2.
   Cancer Res. 2020 Mar 25. pii: 0008-5472.CAN-19-3095.
   PubMed     Text format     Abstract available
   
   
   
2. ZHAO Y, Kaushik N, Kang JH, Kaushik NK, et al
   A Feedback loop comprising EGF/TGF-alpha Sustains TFCP2-mediated Breast Cancer Progression.
   Cancer Res. 2020 Mar 19. pii: 0008-5472.CAN-19-2908.
   PubMed     Text format     Abstract available
   
   
   
3. FLACH KD, Periyasamy M, Jadhav A, Dorjsuren D, et al
   Endonuclease FEN1 coregulates ERalpha activity and provides a novel drug interface in tamoxifen resistant breast cancer.
   Cancer Res. 2020 Mar 19. pii: 0008-5472.CAN-19-2207.
   PubMed     Text format     Abstract available
   
   
   
4. LUO ML, Zheng F, Chen W, Liang ZM, et al
   Inactivation of the prolyl isomerase Pin1 sensitizes BRCA1-proficient breast cancer to PARP inhibition.
   Cancer Res. 2020 Mar 19. pii: 0008-5472.CAN-19-2739.
   PubMed     Text format     Abstract available
   
   
   
5. MAJORINI MT, Cancila V, Rigoni A, Botti L, et al
   Infiltrating mast cell-mediated stimulation of estrogen receptor activity in breast cancer cells promotes the luminal phenotype.
   Cancer Res. 2020 Mar 16. pii: 0008-5472.CAN-19-3596.
   PubMed     Text format     Abstract available
   
   
   February 2020
6. BORGES VF, Lyons TR, Germain D, Schedin P, et al
   Postpartum involution and cancer: an opportunity for targeted breast cancer prevention and treatments?
   Cancer Res. 2020 Feb 19. pii: 0008-5472.CAN-19-3448.
   PubMed     Text format     Abstract available
   
   
   
7. HEBERT JD, Myers SA, Naba A, Abbruzzese G, et al
   Proteomic profiling of the ECM of xenograft breast cancer metastases in different organs reveals distinct metastatic niches.
   Cancer Res. 2020 Feb 4. pii: 0008-5472.CAN-19-2961.
   PubMed     Text format     Abstract available
   
   
   
8. MALLETER M, Tauzin S, Bessede A, Castellano R, et al
   Correction: CD95L Cell Surface Cleavage Triggers a Prometastatic Signaling Pathway in Triple-Negative Breast Cancer.
   Cancer Res. 2020;80:639.
   PubMed     Text format    
   
   
   January 2020
9. JANG JH, Kim DH, Lim JM, Lee JW, et al
   Breast cancer cell-derived soluble CD44 promotes tumor progression by triggering macrophage IL-1beta production.
   Cancer Res. 2020 Jan 22. pii: 0008-5472.CAN-19-2288.
   PubMed     Text format     Abstract available
   
   
   
10. ECKHARDT BL, Cao Y, Redfern AD, Chi LH, et al
    Activation of canonical BMP4-SMAD7 signaling suppresses breast cancer metastasis.
    Cancer Res. 2020 Jan 15. pii: 0008-5472.CAN-19-0743.
    PubMed     Text format     Abstract available
    
    
    
11. SANTORO AL, Drummond RD, da Silva IT, Ferreira SS, et al
    In situ DESI - MSI lipidomic profiles of breast cancer molecular subtypes and precursor lesions.
    Cancer Res. 2020 Jan 7. pii: 0008-5472.CAN-18-3574.
    PubMed     Text format     Abstract available
    
    
    
12. SANCHEZ-GONZALEZ I, Bobien A, Molnar C, Schmid S, et al
    miR-149 suppresses breast cancer metastasis by blocking paracrine interactions with macrophages.
    Cancer Res. 2020 Jan 7. pii: 0008-5472.CAN-19-1934.
    PubMed     Text format     Abstract available
    
    
    
13. NIU Y, Bao L, Chen Y, Wang C, et al
    HIF-2-induced long non-coding RNA RAB11B-AS1 promotes hypoxia-mediated angiogenesis and breast cancer metastasis.
    Cancer Res. 2020 Jan 3. pii: 0008-5472.CAN-19-1532.
    PubMed     Text format     Abstract available
    
    
    
14. NIEHOFF NM, White AJ, Sandler DP
    Physical Activity and Breast Cancer: Focusing on High-Risk Subgroups and Putting Recommendations in Context.
    Cancer Res. 2020;80:23-24.
    PubMed     Text format     Abstract available
    
    
    December 2019
15. CITRON F, Segatto I, Rampioni Vinciguerra GL, Musco L, et al
    Downregulation of miR-223 expression is an early event during mammary transformation and confers resistance to CDK4/6 inhibitors in luminal breast cancer.
    Cancer Res. 2019 Dec 20. pii: 0008-5472.CAN-19-1793.
    PubMed     Text format     Abstract available
    
    
    
16. MOYER CL, Ivanovich J, Gillespie JL, Doberstein R, et al
    Rare BRIP1 missense alleles confer risk for ovarian and breast cancer.
    Cancer Res. 2019 Dec 10. pii: 0008-5472.CAN-19-1991.
    PubMed     Text format     Abstract available
    
    
    November 2019
17. XIAO G, Lundine D, Annor GK, Canar J, et al
    Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer.
    Cancer Res. 2019 Nov 27. pii: 0008-5472.CAN-19-1036.
    PubMed     Text format     Abstract available
    
    
    
18. CHIODONI C, Cancila V, Renzi TA, Perrone M, et al
    Transcriptional profiles and stromal changes reveal bone marrow adaptation to early breast cancer in association with deregulated circulating microRNAs.
    Cancer Res. 2019 Nov 27. pii: 0008-5472.CAN-19-1425.
    PubMed     Text format     Abstract available
    
    
    
19. CHEN R, Goodison S, Sun Y
    Molecular profiles of matched primary and metastatic tumor samples support a linear evolutionary model of breast cancer.
    Cancer Res. 2019 Nov 19. pii: 0008-5472.CAN-19-2296.
    PubMed     Text format     Abstract available
    
    
    
20. AUNG A, Kumar V, Theprungsirikul J, Davey SK, et al
    An engineered tumor-on-a-chip device with breast cancer-immune cell interactions for assessing T-cell recruitment.
    Cancer Res. 2019 Nov 19. pii: 0008-5472.CAN-19-0342.
    PubMed     Text format     Abstract available
    
    
    
21. LOURENCO AR, Ban Y, Crowley MJ, Lee SB, et al
    Differential contributions of pre- and post- EMT tumor cells in breast cancer metastasis.
    Cancer Res. 2019 Nov 8. pii: 0008-5472.CAN-19-1427.
    PubMed     Text format     Abstract available
    
    
    
22. UMEH-GARCIA M, Simion C, Ho PY, Batra N, et al
    A Novel Bioengineered MicroRNA-127 Prodrug Suppresses The Growth And Metastatic Potential Of Triple Negative Breast Cancer Cells.
    Cancer Res. 2019 Nov 6. pii: 0008-5472.CAN-19-0656.
    PubMed     Text format     Abstract available
    
    
    October 2019
23. BARBIE TU, Ritter JL, Zhu Z, Thai TC, et al
    Phosphorylation of RAB7 by TBK1/IKKepsilon Regulates Innate Immune Signaling in Triple Negative Breast Cancer.
    Cancer Res. 2019 Oct 29. pii: 0008-5472.CAN-19-1310.
    PubMed     Text format     Abstract available
    
    
    
24. JIA M, Andreassen T, Jensen L, Bathen TF, et al
    Editor's Note: Estrogen Receptor alpha Promotes Breast Cancer by Reprogramming Choline Metabolism.
    Cancer Res. 2019;79:5458.
    PubMed     Text format    
    
    
    
25. KEHM RD, Genkinger JM, MacInnis RJ, John EM, et al
    Recreational physical activity is associated with reduced breast cancer risk in adult women at high risk for breast cancer: a cohort study of women selected for familial and genetic risk.
    Cancer Res. 2019 Oct 2. pii: 0008-5472.CAN-19-1847.
    PubMed     Text format     Abstract available
    
    
    September 2019
26. HATA T, Rajabi H, Takahashi H, Yasumizu Y, et al
    MUC1-C Activates The NuRD Complex To Drive Dedifferentiation of Triple-Negative Breast Cancer Cells.
    Cancer Res. 2019 Sep 13. pii: 0008-5472.CAN-19-1034.
    PubMed     Text format     Abstract available
    
    
    
27. HERMANO E, Goldberg R, Rubinstein AM, Sonnenblick A, et al
    Heparanase accelerates obesity-associated breast cancer progression.
    Cancer Res. 2019 Sep 3. pii: 0008-5472.CAN-18-4058.
    PubMed     Text format     Abstract available
    
    
    August 2019
28. YANG T, Ren C, Lu C, Qiao P, et al
    Phosphorylation of HSF1 by PIM2 induces PD-L1 expression and promotes tumor growth in breast cancer.
    Cancer Res. 2019 Aug 13. pii: 0008-5472.CAN-19-0063.
    PubMed     Text format     Abstract available
    
    
    
29. PEIFFER DS, Wyatt D, Zlobin A, Piracha A, et al
    DAXX Suppresses Tumor-Initiating Cells in Estrogen Receptor-positive Breast Cancer following endocrine therapy.
    Cancer Res. 2019 Aug 6. pii: 0008-5472.CAN-19-1110.
    PubMed     Text format     Abstract available
    
    
    July 2019
30. WANG MY, Chen PS, Prakash E, Hsu HC, et al
    Editor's Note: Connective Tissue Growth Factor Confers Drug Resistance in Breast Cancer through Concomitant Up-regulation of Bcl-xL and cIAP1.
    Cancer Res. 2019;79:3792.
    PubMed     Text format    
    
    
    
31. INGMAN WV
    The Gut Microbiome: A New Player in Breast Cancer Metastasis.
    Cancer Res. 2019;79:3539-3541.
    PubMed     Text format     Abstract available
    
    
    
32. YE S, Ding YF, Jia WH, Liu XL, et al
    SET domain-containing protein 4 epigenetically controls breast cancer stem cell quiescence.
    Cancer Res. 2019 Jul 15. pii: 0008-5472.CAN-19-1084.
    PubMed     Text format     Abstract available
    
    
    
33. PRIETO-VILA M, Usuba W, Takahashi RU, Shimomura I, et al
    Single-cell Analysis Reveals a Preexisting Drug-Resistant Subpopulation in the Luminal Breast Cancer Subtype.
    Cancer Res. 2019 Jul 9. pii: 0008-5472.CAN-19-0122.
    PubMed     Text format     Abstract available
    
    
    
34. HE L, Yuan L, Sun Y, Wang P, et al
    Glucocorticoid receptor signaling activates TEAD4 to promote breast cancer progression.
    Cancer Res. 2019 Jul 9. pii: 0008-5472.CAN-19-0012.
    PubMed     Text format     Abstract available
    
    
    June 2019
35. ACHARYA S, Yao J, Li P, Zhang C, et al
    Sphingosine-kinase-1 signaling promotes metastasis of triple-negative breast cancer.
    Cancer Res. 2019 Jun 25. pii: 0008-5472.CAN-18-3803.
    PubMed     Text format     Abstract available
    
    
    
36. PELUFFO G, Subedee A, Harper NW, Kingston N, et al
    EN1 is a transcriptional dependency in triple-negative breast cancer associated with brain metastasis.
    Cancer Res. 2019 Jun 25. pii: 0008-5472.CAN-18-3264.
    PubMed     Text format     Abstract available
    
    
    
37. GOMEZ-MIRAGAYA J, Diaz-Navarro A, Tonda R, Beltran S, et al
    Chromosome 12p amplification in triple-negative/BRCA1-mutated breast cancer associates with emergence of docetaxel resistance and carboplatin sensitivity.
    Cancer Res. 2019 Jun 18. pii: 0008-5472.CAN-18-3835.
    PubMed     Text format     Abstract available
    
    
    
38. JARDIM-PERASSI BV, Huang S, Dominguez-Viqueira W, Poleszczuk J, et al
    Multiparametric MRI and co-registered histology identify tumor habitats in breast cancer mouse models.
    Cancer Res. 2019 Jun 11. pii: 0008-5472.CAN-19-0213.
    PubMed     Text format     Abstract available
    
    
    
39. MANSOUR M, Haupt S, Chan AL, Godde N, et al
    Retraction: The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling.
    Cancer Res. 2019;79:3008.
    PubMed     Text format    
    
    
    May 2019
40. LAI X, Geier OM, Fleischer T, Garred O, et al
    Towards personalized computer simulation of breast cancer treatment: a multi-scale pharmacokinetic and pharmacodynamic model informed by multi-type patient data.
    Cancer Res. 2019 May 22. pii: 0008-5472.CAN-18-1804.
    PubMed     Text format     Abstract available
    
    
    
41. SHEN M, Dong C, Ruan X, Yan W, et al
    Chemotherapy-induced extracellular vesicle miRNAs promote breast cancer stemness by targeting ONECUT2.
    Cancer Res. 2019 May 22. pii: 0008-5472.CAN-18-4055.
    PubMed     Text format     Abstract available
    
    
    
42. PRABAKARAN I, Wu Z, Lee C, Tong B, et al
    Gaussian mixture models for probabilistic classification of breast cancer.
    Cancer Res. 2019 May 21. pii: 0008-5472.CAN-19-0573.
    PubMed     Text format     Abstract available
    
    
    
43. RON A, Dean-Ben XL, Gottschalk S, Razansky D, et al
    Volumetric optoacoustic imaging unveils high-resolution patterns of acute and cyclic hypoxia in a murine model of breast cancer.
    Cancer Res. 2019 May 16. pii: 0008-5472.CAN-18-3769.
    PubMed     Text format     Abstract available
    
    
    
44. BUCHTA ROSEAN C, Bostic RR, Ferey JCM, Feng TY, et al
    Pre-existing commensal dysbiosis is a host-intrinsic regulator of tissue inflammation and tumor cell dissemination in hormone receptor-positive breast cancer.
    Cancer Res. 2019 May 7. pii: 0008-5472.CAN-18-3464.
    PubMed     Text format     Abstract available
    
    
    
45. STEWART RL, Updike KL, Factor RE, Henry NL, et al
    A multigene assay determines risk of recurrence in patients with triple-negative breast cancer.
    Cancer Res. 2019 May 2. pii: 0008-5472.CAN-18-3014.
    PubMed     Text format     Abstract available
    
    
    
46. VALETA-MAGARA A, Gadi A, Volta V, Walters B, et al
    Inflammatory Breast Cancer Promotes Development of M2 Tumor-associated Macrophages and Cancer Mesenchymal Cells Through a Complex Cytokine Network.
    Cancer Res. 2019 May 1. pii: 0008-5472.CAN-17-2158.
    PubMed     Text format     Abstract available
    
    
    
47. MCANDREWS KM, Kalluri R
    Nischarin Regulates Secretion of Exosomes and Cancer Progression.
    Cancer Res. 2019;79:2099-2101.
    PubMed     Text format     Abstract available
    
    
    April 2019
48. LIU LM, Sun WZ, Fan XZ, Xu YL, et al
    Methylation of C/EBPalpha by PRMT1 inhibits its tumor suppressive function in breast cancer.
    Cancer Res. 2019 Apr 23. pii: 0008-5472.CAN-18-3211.
    PubMed     Text format     Abstract available
    
    
    
49. TRUONG DD, Kratz A, Park JG, Barrientos ES, et al
    A human organotypic microfluidic tumor model permits investigation of the interplay between patient-derived fibroblasts and breast cancer cells.
    Cancer Res. 2019 Apr 16. pii: 0008-5472.CAN-18-2293.
    PubMed     Text format     Abstract available
    
    
    
50. SHARMA D
    Quest for Tangible Biomarkers for Triple-Negative Breast Cancer.
    Cancer Res. 2019;79:1746-1748.
    PubMed     Text format     Abstract available
    
    
    
51. COLOMBO MP, Lecis D
    When Failure Is Worse Than Giving Up: The Case of CTL.
    Cancer Res. 2019;79:1753-1755.
    PubMed     Text format     Abstract available
    
    
    
52. ZHANG H, Zhang N, Liu Y, Su P, et al
    Epigenetic regulation of NAMPT by NAMPT-AS drives metastatic progression in triple-negative breast cancer.
    Cancer Res. 2019 Apr 2. pii: 0008-5472.CAN-18-3418.
    PubMed     Text format     Abstract available
    
    
    
53. JUNG SY, Papp JC, Sobel EM, Yu H, et al
    Breast cancer risk and insulin resistance: post genome-wide gene-environment interaction study using a random survival forest.
    Cancer Res. 2019 Apr 1. pii: 0008-5472.CAN-18-3688.
    PubMed     Text format     Abstract available
    
    
    March 2019
54. YIN T, Zhao ZB, Guo J, Wang T, et al
    Aurora-A inhibition eliminates myeloid cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in breast cancer.
    Cancer Res. 2019 Mar 22. pii: 0008-5472.CAN-18-3397.
    PubMed     Text format     Abstract available
    
    
    
55. COX OT, Edmunds SJ, Simon-Keller K, Li B, et al
    PDLIM2 is a marker of adhesion and beta-catenin activity in triple-negative breast cancer.
    Cancer Res. 2019 Mar 18. pii: 0008-5472.CAN-18-2787.
    PubMed     Text format     Abstract available
    
    
    
56. BIRGE RB, Kasikara C, Davra V, Calianese D, et al
    Pan-TAM tyrosine kinase inhibitor BMS-777607 enhances anti-PD-1 mAb efficacy in a murine model of triple-negative breast cancer.
    Cancer Res. 2019 Mar 15. pii: 0008-5472.CAN-18-2614.
    PubMed     Text format     Abstract available
    
    
    
57. MADAK-ERDOGAN Z, Band S, Zhao YC, Smith BP, et al
    Free fatty acids rewire cancer metabolism in obesity-associated breast cancer via estrogen receptor and mTOR signaling.
    Cancer Res. 2019 Mar 12. pii: 0008-5472.CAN-18-2849.
    PubMed     Text format     Abstract available
    
    
    
58. YAMAMOTO M, Jin C, Hata T, Yasumizu Y, et al
    MUC1-C INTEGRATES CHROMATIN REMODELING AND PARP1 ACTIVITY IN THE DNA DAMAGE RESPONSE OF TRIPLE-NEGATIVE BREAST CANCER CELLS.
    Cancer Res. 2019 Mar 1. pii: 0008-5472.CAN-18-3259.
    PubMed     Text format     Abstract available
    
    
    February 2019
59. BHOLA NE, Jansen VM, Bafna S, Giltnane JM, et al
    Correction: Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer.
    Cancer Res. 2019;79:876.
    PubMed     Text format    
    
    
    
60. BHOLA NE, Jansen VM, Koch JP, Li H, et al
    Correction: Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.
    Cancer Res. 2019;79:875.
    PubMed     Text format    
    
    
    
61. JANSEN VM, Bhola NE, Bauer JA, Formisano L, et al
    Correction: Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.
    Cancer Res. 2019;79:874.
    PubMed     Text format    
    
    
    
62. HANKER AB, Estrada MV, Bianchini G, Moore PD, et al
    Correction: Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2(+) Breast Cancer.
    Cancer Res. 2019;79:873.
    PubMed     Text format    
    
    
    
63. HONG BS, Ryu HS, Kim N, Kim J, et al
    Tumor suppressor microRNA-204-5p regulates growth, metastasis, and immune microenvironment remodeling in breast cancer.
    Cancer Res. 2019 Feb 8. pii: 0008-5472.CAN-18-0891.
    PubMed     Text format     Abstract available
    
    
    
64. SHINDE A, Hardy SD, Kim D, Akhand SS, et al
    Spleen tyrosine kinase-mediated autophagy is required for epithelial-mesenchymal plasticity and metastasis in breast cancer.
    Cancer Res. 2019 Feb 7. pii: 0008-5472.CAN-18-2636.
    PubMed     Text format     Abstract available
    
    
    January 2019
65. STEIN RG, Ebert S, Schlahsa L, Scholz CJ, et al
    Cognate Non-Lytic Interactions between CD8+ T cells and Breast Cancer Cells Induce Cancer Stem Cell-like Properties.
    Cancer Res. 2019 Jan 28. pii: 0008-5472.CAN-18-0387.
    PubMed     Text format     Abstract available
    
    
    
66. MAZIVEYI M, Dong S, Baranwal S, Mehrnezhad A, et al
    Exosomes from Nischarin-Expressing Cells Reduce Breast Cancer Cell Motility and tumor growth.
    Cancer Res. 2019 Jan 11. pii: 0008-5472.CAN-18-0842.
    PubMed     Text format     Abstract available
    
    
    
67. KHAWALED S, Suh SS, Abdeen SK, Monin J, et al
    WWOX inhibits metastasis of triple-negative breast cancer cells via modulation of microRNAs.
    Cancer Res. 2019 Jan 8. pii: 0008-5472.CAN-18-0614.
    PubMed     Text format     Abstract available
    
    
    
68. XIANG Y, Yan K, Zheng Q, Ke H, et al
    Histone Demethylase KDM4B Promotes DNA Damage by Activating Long Interspersed Nuclear Element-1.
    Cancer Res. 2019;79:86-98.
    PubMed     Text format     Abstract available
    
    
    
69. BAO J, Di Lorenzo A, Lin K, Lu Y, et al
    Mouse Models of Overexpression Reveal Distinct Oncogenic Roles for Different Type I Protein Arginine Methyltransferases.
    Cancer Res. 2019;79:21-32.
    PubMed     Text format     Abstract available
    
    
    December 2018
70. YANG F, Takagaki Y, Yoshitomi Y, Ikeda T, et al
    Inhibition of dipeptidyl peptidase-4 accelerates epithelial-mesenchymal transition and breast cancer metastasis via the CXCL12/CXCR4/mTOR axis.
    Cancer Res. 2018 Dec 24. pii: 0008-5472.CAN-18-0620.
    PubMed     Text format     Abstract available
    
    
    
71. EL AYACHI I, Fatima I, Wend P, Alva-Ornelas JA, et al
    The WNT10B network is associated with survival and metastases in chemoresistant triple-negative breast cancer.
    Cancer Res. 2018 Dec 18. pii: 0008-5472.CAN-18-1069.
    PubMed     Text format     Abstract available
    
    
    November 2018
72. NILCHIAN A, Johansson J, Ghalali A, Travica Asanin S, et al
    CXADR-Mediated Formation of an AKT Inhibitory Signalosome at Tight Junctions Controls Epithelial-Mesenchymal Plasticity in Breast Cancer.
    Cancer Res. 2018 Nov 1. pii: 0008-5472.CAN-18-1742.
    PubMed     Text format     Abstract available
    
    
    
73. LI J, Ugalde-Morales E, Wen WX, Decker B, et al
    Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer.
    Cancer Res. 2018;78:6329-6338.
    PubMed     Text format     Abstract available
    
    
    October 2018
74. 
    Correction: Absence of the Full-Length Breast Cancer-Associated Gene-1 Leads to Increased Expression of Insulin-Like Growth Factor Signaling Axis Members.
    Cancer Res. 2018;78:6025.
    PubMed     Text format    
    
    
    
75. WANG Z, Grosskurth SE, Cheung T, Petteruti P, et al
    Pharmacological inhibition of PARP6 triggers multipolar spindle formation and elicits therapeutic effects in breast cancer.
    Cancer Res. 2018 Oct 8. pii: 0008-5472.CAN-18-1362.
    PubMed     Text format     Abstract available
    
    
    
76. ALI R, Al-Kawaz A, Toss MS, Green AR, et al
    Targeting PARP1 in XRCC1 deficient sporadic invasive breast cancer or pre-invasive ductal carcinoma in situ induces synthetic lethality and chemoprevention.
    Cancer Res. 2018 Oct 8. pii: 0008-5472.CAN-18-0633.
    PubMed     Text format     Abstract available
    
    
    
77. 
    Retraction: Dicer Elicits Paclitaxel Chemosensitization and Suppresses Cancer Stemness in Breast Cancer by Repressing AXL.
    Cancer Res. 2018;78:5719.
    PubMed     Text format    
    
    
    September 2018
78. ELDER AM, Tamburini BA, Crump LS, Black SA, et al
    Semaphorin 7A promotes macrophage-mediated lymphatic remodeling during postpartum mammary gland involution and in breast cancer.
    Cancer Res. 2018 Sep 25. pii: 0008-5472.CAN-18-1642.
    PubMed     Text format     Abstract available
    
    
    
79. CHEN C, Okita Y, Watanabe Y, Abe F, et al
    Glycoprotein nmb is exposed on the surface of dormant breast cancer cells and induces stem cell-like properties.
    Cancer Res. 2018 Sep 17. pii: 0008-5472.CAN-18-0599.
    PubMed     Text format     Abstract available
    
    
    
80. DINARELLO CA
    An Interleukin-1 Signature in Breast Cancer Treated with Interleukin-1 Receptor Blockade: Implications for Treating Cytokine Release Syndrome of Checkpoint Inhibitors.
    Cancer Res. 2018;78:5200-5202.
    PubMed     Text format     Abstract available
    
    
    
81. GAUDET MM, Gierach GL, Carter BD, Luo J, et al
    Pooled analysis of nine cohorts reveals breast cancer risk factors by tumor molecular subtype.
    Cancer Res. 2018 Sep 5. pii: 0008-5472.CAN-18-0502.
    PubMed     Text format     Abstract available
    
    
    
82. 
    Retraction: Zerumbone Abolishes RANKL-Induced NF-kappaB Activation, Inhibits Osteoclastogenesis, and Suppresses Human Breast Cancer-Induced Bone Loss in Athymic Nude Mice.
    Cancer Res. 2018;78:5186.
    PubMed     Text format    
    
    
    August 2018
83. HUANG F, Shi Q, Li Y, Xu L, et al
    HER2/EGFR-AKT signaling switches TGF-beta from inhibiting cell proliferation to promoting cell migration in breast cancer.
    Cancer Res. 2018 Aug 31. pii: 0008-5472.CAN-18-0136.
    PubMed     Text format     Abstract available
    
    
    
84. YANOVICH G, Agmon H, Harel M, Sonnenblick A, et al
    Clinical Proteomics of Breast Cancer Reveals a Novel Layer of Breast Cancer Classification.
    Cancer Res. 2018 Aug 28. pii: 0008-5472.CAN-18-1079.
    PubMed     Text format     Abstract available
    
    
    
85. AL ABSI A, Wurzer H, Guerin CL, Hoffmann C, et al
    Actin cytoskeleton remodeling drives breast cancer cell escape from natural killer-mediated cytotoxicity.
    Cancer Res. 2018 Aug 13. pii: 0008-5472.CAN-18-0441.
    PubMed     Text format     Abstract available
    
    
    
86. MURALI B, Ren Q, Luo X, Faget DV, et al
    Inhibition of the stromal p38MAPK/MK2 pathway limits breast cancer metastases and chemotherapy-induced bone loss.
    Cancer Res. 2018 Aug 9. pii: 0008-5472.CAN-18-0234.
    PubMed     Text format     Abstract available
    
    
    
87. ZHANG FL, Cao JL, Xie HY, Sun R, et al
    Cancer-associated MORC2 mutant M276I regulates an hnRNPM-mediated CD44 splicing switch to promote invasion and metastasis in triple-negative breast cancer.
    Cancer Res. 2018 Aug 9. pii: 0008-5472.CAN-17-1394.
    PubMed     Text format     Abstract available
    
    
    
88. ZHOU R, Bagga P, Nath K, Hariharan H, et al
    Glutamate-weighted chemical exchange saturation transfer magnetic resonance imaging (GluCEST MRI) detects glutaminase inhibition in a mouse model of triple-negative breast cancer.
    Cancer Res. 2018 Aug 2. pii: 0008-5472.CAN-17-3988.
    PubMed     Text format     Abstract available
    
    
    July 2018
89. UBELLACKER JM, Baryawno N, Severe N, DeCristo MJ, et al
    Modulating bone marrow hematopoietic lineage potential to prevent bone metastasis in breast cancer.
    Cancer Res. 2018 Jul 31. pii: 0008-5472.CAN-18-0548.
    PubMed     Text format     Abstract available
    
    
    
90. CROSET M, Pantano F, Kan CWS, Bonnelye E, et al
    MicroRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis-associated genes.
    Cancer Res. 2018 Jul 24. pii: 0008-5472.CAN-17-3058.
    PubMed     Text format     Abstract available
    
    
    
91. XING F, Liu Y, Wu SY, Wu K, et al
    Loss of XIST in Breast Cancer Activates MSN-c-Met and Reprograms Microglia via Exosomal miRNA to Promote Brain Metastasis.
    Cancer Res. 2018 Jul 19. pii: 0008-5472.CAN-18-1102.
    PubMed     Text format     Abstract available
    
    
    
92. WU TC, Xu K, Martinek J, Young RR, et al
    IL-1 receptor antagonist controls transcriptional signature of inflammation in patients with metastatic breast cancer.
    Cancer Res. 2018 Jul 16. pii: 0008-5472.CAN-18-0413.
    PubMed     Text format     Abstract available
    
    
    
93. XING Z, Zhang Y, Liang K, Yan L, et al
    Expression of long non-coding RNA YIYA promotes glycolysis in breast cancer.
    Cancer Res. 2018 Jul 2. pii: 0008-5472.CAN-17-0385.
    PubMed     Text format     Abstract available
    
    
    June 2018
94. ZHANG W, Wu M, Chong QY, Zhang M, et al
    Loss of estrogen-regulated MIR135A1 at 3p21.1 promotes tamoxifen resistance in breast cancer.
    Cancer Res. 2018 Jun 26. pii: 0008-5472.CAN-18-0069.
    PubMed     Text format     Abstract available
    
    
    
95. SUN R, Xie HY, Qian JX, Huang YN, et al
    FBXO22 possesses both pro-tumorigenic and anti-metastatic roles in breast cancer progression.
    Cancer Res. 2018 Jun 26. pii: 0008-5472.CAN-17-3647.
    PubMed     Text format     Abstract available
    
    
    
96. IM YK, Najyb O, Gravel SP, McGuirk S, et al
    Interplay between ShcA signaling and PGC-1alpha triggers targetable metabolic vulnerabilities in breast cancer.
    Cancer Res. 2018 Jun 21. pii: 0008-5472.CAN-17-3696.
    PubMed     Text format     Abstract available
    
    
    
97. 
    Correction: TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer.
    Cancer Res. 2018;78:3403.
    PubMed     Text format    
    
    
    
98. HE JP, Hou PP, Chen QT, Wang WJ, et al
    Flightless-I blocks p62-mediated recognition of LC3 to impede selective autophagy and promote breast cancer progression.
    Cancer Res. 2018 Jun 13. pii: 0008-5472.CAN-17-3835.
    PubMed     Text format     Abstract available
    
    
    
99. GOOD CR, Panjarian S, Kelly AD, Madzo J, et al
    TET1-mediated hypomethylation activates oncogenic signaling in triple-negative breast cancer.
    Cancer Res. 2018 Jun 11. pii: 0008-5472.CAN-17-2082.
    PubMed     Text format     Abstract available
    
    
    
100. LU H, Tran L, Park Y, Chen I, et al
     Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF-1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment.
     Cancer Res. 2018 Jun 7. pii: 0008-5472.CAN-18-0270.
     PubMed     Text format     Abstract available
     
     
     May 2018
101. JASTRZEBSKI K, Thijssen B, Kluin RJ, de Lint K, et al
     Integrative modeling identifies key determinants of inhibitor sensitivity in breast cancer cell lines.
     Cancer Res. 2018 May 29. pii: 0008-5472.CAN-17-2698.
     PubMed     Text format     Abstract available
     
     
     
102. MATSUNAGA N, Ogino T, Hara Y, Tanaka T, et al
     Optimized dosing schedule based on circadian dynamics of mouse breast cancer stem cells improves the anti-tumor effects of aldehyde dehydrogenase.
     Cancer Res. 2018 May 7. pii: 0008-5472.CAN-17-4034.
     PubMed     Text format     Abstract available
     
     
     April 2018
103. ZHENG YZ, Xue MZ, Shen HJ, Li XG, et al
     PHF5A Epigenetically Inhibits Apoptosis to Promote Breast Cancer Progression.
     Cancer Res. 2018 Apr 26. pii: 0008-5472.CAN-17-3514.
     PubMed     Text format     Abstract available
     
     
     
104. AVANZATO D, Pupo E, Ducano N, Isella C, et al
     High USP6NL levels in breast cancer sustain chronic AKT phosphorylation and GLUT1 stability fueling aerobic glycolysis.
     Cancer Res. 2018 Apr 24. pii: 0008-5472.CAN-17-3018.
     PubMed     Text format     Abstract available
     
     
     March 2018
105. WANG LH, Tseng CW, Kuo WH, Chan SH, et al
     Transketolase regulates the metabolic switch to control breast cancer cell metastasis via the alpha-ketoglutarate signaling pathway.
     Cancer Res. 2018 Mar 29. pii: 0008-5472.CAN-17-2906.
     PubMed     Text format     Abstract available
     
     
     
106. ZHANG B, Chen MY, Sheng YJ, Zhuo XB, et al
     A large-scale, exome-wide association study of Han Chinese women identifies three novel loci predisposing to breast cancer.
     Cancer Res. 2018 Mar 23. pii: 0008-5472.CAN-17-1721.
     PubMed     Text format     Abstract available
     
     
     
107. REN D, Zhu X, Kong R, Zhao Z, et al
     Targeting Brain-Adaptive Cancer Stem Cells Prohibits Brain Metastatic Colonization of Triple-Negative Breast Cancer.
     Cancer Res. 2018 Mar 22. pii: 0008-5472.CAN-17-2994.
     PubMed     Text format     Abstract available
     
     
     
108. HOU J, Williams J, Botvinick E, Potma E, et al
     Visualization of breast cancer metabolism using multimodal non-linear optical microscopy of cellular lipids and redox state.
     Cancer Res. 2018 Mar 13. pii: 0008-5472.CAN-17-2618.
     PubMed     Text format     Abstract available
     
     
     
109. LUAN H, Mohapatra B, Bielecki TA, Mushtaq I, et al
     Loss of the nuclear pool of ubiquitin ligase CHIP/STUB1 in breast cancer unleashes the MZF1-cathepsin pro-oncogenic program.
     Cancer Res. 2018 Mar 6. pii: 0008-5472.CAN-16-2140.
     PubMed     Text format     Abstract available
     
     
     February 2018
110. HORNSVELD M, Smits LM, Meerlo M, van Amersfoort M, et al
     FOXO transcription factors both suppress and support breast cancer progression.
     Cancer Res. 2018 Feb 12. pii: 0008-5472.CAN-17-2511.
     PubMed     Text format     Abstract available
     
     
     
111. HAO J, Yan F, Zhang Y, Triplett A, et al
     Expression of adipocyte/macrophage fatty acid binding protein in tumor associated macrophages promotes breast cancer progression.
     Cancer Res. 2018 Feb 6. pii: 0008-5472.CAN-17-2465.
     PubMed     Text format     Abstract available
     
     
     January 2018
112. WERFEL TA, Wang S, Jackson MA, Kavanaugh TE, et al
     Selective mTORC2 inhibitor therapeutically blocks breast cancer cell growth and survival.
     Cancer Res. 2018 Jan 22. pii: 0008-5472.CAN-17-2388.
     PubMed     Text format     Abstract available
     
     
     
113. JIAO X, Velasco-Velazquez MA, Wang M, Li Z, et al
     CCR5 governs DNA damage and breast cancer stem cell expansion.
     Cancer Res. 2018 Jan 22. pii: 0008-5472.CAN-17-0915.
     PubMed     Text format     Abstract available
     
     
     
114. LUDWIK KA, McDonald OG, Brenin DR, Lannigan DA, et al
     ERalpha-mediated nuclear sequestration of RSK2 is required for ER+ breast cancer tumorigenesis.
     Cancer Res. 2018 Jan 19. pii: 0008-5472.CAN-17-2063.
     PubMed     Text format     Abstract available
     
     
     
115. ZHANG Y, Manjunath M, Zhang S, Chasman D, et al
     Integrative genomic analysis predicts causative cis-regulatory mechanisms of the breast cancer-associated genetic variant rs4415084.
     Cancer Res. 2018 Jan 19. pii: 0008-5472.CAN-17-3486.
     PubMed     Text format     Abstract available
     
     
     
116. NAGAHASHI M, Yamada A, Katsuta E, Aoyagi T, et al
     Targeting the SphK1/S1P/S1PR1 axis that links obesity, chronic inflammation and breast cancer metastasis.
     Cancer Res. 2018 Jan 19. pii: 0008-5472.CAN-17-1423.
     PubMed     Text format     Abstract available
     
     
     
117. EVANS MK, Brown MC, Geradts J, Bao X, et al
     XIAP regulation by MNK links MAPK and NFkappaB signaling to determine an aggressive breast cancer phenotype.
     Cancer Res. 2018 Jan 19. pii: 0008-5472.CAN-17-1667.
     PubMed     Text format     Abstract available
     
     
     
118. SAHA M, Kumar S, Bukhari S, Balaji SA, et al
     AMPK-AKT double negative feedback loop in breast cancer cells regulates their adaptation to matrix deprivation.
     Cancer Res. 2018 Jan 16. pii: 0008-5472.CAN-17-2090.
     PubMed     Text format     Abstract available
     
     
     
119. SARVI S, Patel H, Li J, Dodd GL, et al
     Kindlin-1 promotes pulmonary breast cancer metastasis.
     Cancer Res. 2018 Jan 12. pii: 0008-5472.CAN-17-1518.
     PubMed     Text format     Abstract available
     
     
     
120. NOUGAREDE A, Popgeorgiev N, Kassem L, Omarjee S, et al
     Breast cancer targeting through inhibition of the endoplasmic reticulum-based apoptosis regulator Nrh/BCL2L10.
     Cancer Res. 2018 Jan 12. pii: 0008-5472.CAN-17-0846.
     PubMed     Text format     Abstract available
     
     
     December 2017
121. MAEDA T, Hiraki M, Jin C, Rajabi H, et al
     MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer.
     Cancer Res. 2017 Dec 20. pii: 0008-5472.CAN-17-1636.
     PubMed     Text format     Abstract available
     
     
     
122. EKAMBARAM P, Lee JL, Hubel NE, Hu D, et al
     The CARMA3-Bcl10-MALT1 Signalosome Drives NF-kappaB Activation and Promotes Aggressiveness in Angiotensin II Receptor-positive Breast Cancer.
     Cancer Res. 2017 Dec 19. pii: 0008-5472.CAN-17-1089.
     PubMed     Text format     Abstract available
     
     
     
123. SHARMA C, Wang HX, Li Q, Knoblich K, et al
     Protein Acyltransferase DHHC3 Regulates Breast Tumor Growth, Oxidative Stress, and Senescence.
     Cancer Res. 2017;77:6880-6890.
     PubMed     Text format     Abstract available
     
     
     
124. PAOLETTI C, Cani AK, Larios JM, Hovelson DH, et al
     Comprehensive mutation and copy number profiling in archived circulating breast cancer tumor cells documents heterogeneous resistance mechanisms.
     Cancer Res. 2017 Dec 12. pii: 0008-5472.CAN-17-2686.
     PubMed     Text format     Abstract available
     
     
     
125. TELONIS AG, Rigoutsos I
     Race disparities in the contribution of miRNA isoforms and tRNA-derived fragments to triple-negative breast cancer.
     Cancer Res. 2017 Dec 11. pii: 0008-5472.CAN-17-1947.
     PubMed     Text format     Abstract available
     
     
     
126. EL-SHENNAWY L, Dubrovskyi O, Kastrati I, Danes JM, et al
     Coactivation of estrogen receptor and IKK-beta induces a dormant metastatic phenotype in ER-positive breast cancer.
     Cancer Res. 2017 Dec 11. pii: 0008-5472.CAN-17-1686.
     PubMed     Text format     Abstract available
     
     
     
127. WU Y, Zhang Z, Cenciarini ME, Proietti CJ, et al
     Tamoxifen resistance in breast cancer is regulated by the EZH2-ERalpha-GREB1 transcriptional axis.
     Cancer Res. 2017 Dec 6. pii: 0008-5472.CAN-17-1327.
     PubMed     Text format     Abstract available
     
     
     November 2017
128. HOU P, Li L, Chen F, Chen Y, et al
     PTBP3-mediated regulation of ZEB1 mRNA stability promotes epithelial-mesenchymal transition in breast cancer.
     Cancer Res. 2017 Nov 29. pii: 0008-5472.CAN-17-0883.
     PubMed     Text format     Abstract available
     
     
     
129. EMERSON MA, Banegas MP, Chawla N, Achacoso N, et al
     Disparities in Prostate, Lung, Breast, and Colorectal Cancer Survival and Comorbidity Status among Urban American Indians and Alaskan Natives.
     Cancer Res. 2017 Nov 29. pii: 0008-5472.CAN-17-0429.
     PubMed     Text format     Abstract available
     
     
     
130. BYRD TT, Fousek K, Pignata A, Szot C, et al
     TEM8/ANTXR1-specific CAR T cells as a targeted therapy for triple-negative breast cancer.
     Cancer Res. 2017 Nov 28. pii: 0008-5472.CAN-16-1911.
     PubMed     Text format     Abstract available
     
     
     
131. PAJIC M, Froio D, Daly S, Doculara L, et al
     miR-139-5p modulates radiotherapy resistance in breast cancer by repressing multiple gene networks of DNA repair and ROS defense.
     Cancer Res. 2017 Nov 27. pii: 0008-5472.CAN-16-3105.
     PubMed     Text format     Abstract available
     
     
     
132. CAMPBELL TM, Castro MA, deOliveira KG, Ponder BA, et al
     ER alpha binding by transcription factors NFIB and YBX1 enables FGFR2 signalling to modulate estrogen responsiveness in breast cancer.
     Cancer Res. 2017 Nov 27. pii: 0008-5472.CAN-17-1153.
     PubMed     Text format     Abstract available
     
     
     
133. CAREY JP, Karakas C, Bui T, Chen X, et al
     Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple negative breast cancer.
     Cancer Res. 2017 Nov 27. pii: 0008-5472.CAN-17-1494.
     PubMed     Text format     Abstract available
     
     
     
134. PALMER JR, Castro-Webb N, Bertrand K, Bethea TN, et al
     Type II Diabetes and Incidence of Estrogen Receptor Negative Breast Cancer in African American Women.
     Cancer Res. 2017;77:6462-6469.
     PubMed     Text format     Abstract available
     
     
     October 2017
135. PATIN EC, Soulard D, Fleury S, Hassane M, et al
     Type I IFN receptor signalling controls IL-7-dependent accumulation and activity of protumoral IL-17A-producing gammadeltaT cells in breast cancer.
     Cancer Res. 2017 Oct 25. pii: canres.1416.2017.
     PubMed     Text format     Abstract available
     
     
     
136. TURCOTTE M, Allard D, Mittal D, Bareche Y, et al
     CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy.
     Cancer Res. 2017;77:5652-5663.
     PubMed     Text format     Abstract available
     
     
     September 2017
137. ISHIHARA S, Inman DR, Li WJ, Ponik SM, et al
     Mechano-signal transduction in mesenchymal stem cells induces prosaposin secretion to drive the proliferation of breast cancer cells.
     Cancer Res. 2017 Sep 28. pii: canres.0569.2017.
     PubMed     Text format     Abstract available
     
     
     
138. YANG A, Qin S, Schulte BA, Ethier SP, et al
     MYC Inhibition depletes cancer stem-like cells in triple-negative breast cancer.
     Cancer Res. 2017 Sep 26. pii: canres.3452.2016.
     PubMed     Text format     Abstract available
     
     
     
139. TEO ZL, Versaci S, Dushyanthen S, Caramia F, et al
     Combined CDK4/6 and PI3Kalpha inhibition is synergistic and immunogenic in triple negative breast cancer.
     Cancer Res. 2017 Sep 25. pii: canres.2210.2017.
     PubMed     Text format     Abstract available
     
     
     
140. CHEN L, Chubak J, Boudreau DM, Barlow WE, et al
     Diabetes treatments and risks of adverse breast cancer outcomes among early stage breast cancer patients: A SEER-Medicare analysis.
     Cancer Res. 2017 Sep 21. pii: canres.0687.2017.
     PubMed     Text format     Abstract available
     
     
     
141. DAVIES H, Morganella S, Purdie CA, Jang SJ, et al
     Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency.
     Cancer Res. 2017;77:4755-4762.
     PubMed     Text format     Abstract available
     
     
     
142. KATZENELLENBOGEN BS, Zhao Y, Laws MJ, Sanabria Guillen V, et al
     Structurally novel antiestrogens elicit differential responses from constitutively active mutant estrogen receptors in breast cancer cells and tumors.
     Cancer Res. 2017 Sep 13. pii: canres.1265.2017.
     PubMed     Text format     Abstract available
     
     
     
143. DETHLEFSEN C, Hansen LS, Lillelund C, Andersen C, et al
     Exercise-Induced Catecholamines Activate the Hippo Tumor Suppressor Pathway to Reduce Risks of Breast Cancer Development.
     Cancer Res. 2017 Sep 8. doi: 10.1158/0008-5472.CAN-16-3125.
     PubMed     Text format     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: